Send to

Choose Destination
Oncoimmunology. 2018 Sep 6;7(12):e1500674. doi: 10.1080/2162402X.2018.1500674. eCollection 2018.

Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1.

Jeon BN1,2, Kim HR1,2, Chung YS1,2, Na BR1,2, Park H1,2, Hong C1,2, Fatima Y1,2, Oh H1,2, Kim CH1,2, Jun CD1,2.

Author information

School of Life Sciences, GIST, Gwangju, Korea.
Immune Synapse and Cell Therapy Research Center, GIST, Gwangju, Korea.


Correct temporal and spatial control of actin dynamics is essential for the cytotoxic T cell effector function against tumor cells. However, little is known whether actin engineering in tumor-targeted T cells can enhance their antitumor responses, thereby potentiating the adoptive T cell therapy. Here, we report that TAGLN2, a 22-KDa actin-stabilizing protein which is physically associated with lymphocyte function-associated antigen-1 (LFA-1), potentiates the OTI TCR CD8+ T cells to kill the intercellular adhesion molecule-1 (ICAM-1)-positive/OVA-presenting E0771 cells, but not ICAM-1-negative OVA-B16F10 cells, suggesting an 'inside-out' activation of LFA-1, which causes more efficient immunological synapse formation between T cells and tumor cells. Notably, recombinant TAGLN2 fused with the protein transduction domain (TG2P) overcame the disadvantages of viral gene delivery, leading to a significant reduction in tumor growth in mice. TG2P also potentiated the CD19-targeted, chimeric antigen receptor (CAR)-modified T cells to kill Raji B-lymphoma cells. Our findings indicate that activating the TAGLN2-actin-LFA-1 axis is an effective strategy to potentiate the adoptive T-cell immunotherapy.


ICAM-1; LFA-1; PTD; TAGLN2; adoptive T cell therapies; cancer immunotherapy

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center